PRECISELY Targeted Therapies for patients with cancer

With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.

Chemistry at the Core

We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.

Built for Patients

We partner with physician-scientists to identify patient needs and the limitations of existing therapies.

Driven by Purpose

We are passionate about using our expertise to address the needs of patients with cancer.

Stephen McNamara
Finance
Stephen McNamara
Finance
Henry Pelish, PhD
Biology
Henry Pelish, PhD
Henry Pelish, PhD
Biology
Matthew Campbell
Pharmaceutical Development
Matthew Campbell
Pharmaceutical Development
Deb Miller, PhD, JD
Chief Legal Officer
Deb Miller, PhD, JD
Chief Legal Officer
Jason Kropp
Pharmaceutical Development
Jason Kropp
Jason Kropp
Pharmaceutical Development
John Soglia, PhD
Translational Development
John Soglia, PhD
John Soglia, PhD
Translational Development
Yuting Sun, PhD
Biology
Yuting Sun, PhD
Biology
Scot Mente, PhD
Computational Chemistry
Scot Mente, PhD
Scot Mente, PhD
Computational Chemistry
Joshua Horan, PhD
Chemistry
Joshua Horan, PhD
Joshua Horan, PhD
Chemistry
Nathan McConarty, JD
Legal
Nathan McConarty, JD
Legal
Christian Martin
Translational Development
Christian Martin
Translational Development
Allison Ciborowski
Quality Assurance
Allison Ciborowski
Quality Assurance
Brenda Vienneau, CPA, CMA
Finance
Brenda Vienneau, CPA, CMA
Finance
Anupong
Tangpeerachaikul, PhD
Biology
Anupong Tangpeerachaikul, PhD
Anupong
Tangpeerachaikul, PhD
Biology
Kristi Byrnes
Quality Assurance
Kristi Byrnes
Quality Assurance
Paula Chubet
Legal
Paula Chubet
Legal
Morgan Maiola
Quality Assurance
Morgan Maiola
Quality Assurance
Joshua Lance, JD
Legal
Joshua Lance, JD
Legal
Tina Kehrig
Clinical Operations
Tina Kehrig
Clinical Operations
Baudouin Gerard, PhD
Medicinal Chemistry
Baudouin Gerard, PhD
Baudouin Gerard, PhD
Medicinal Chemistry
Ruth Adams
Clinical Operations
Ruth Adams
Ruth Adams
Clinical Operations
Shannon Dauksis, PharmD
Program Management
Shannon Dauksis, PharmD
Program Management
Viola Zhu, MD, PhD
Clinical Development
Viola Zhu, MD, PhD
Clinical Development
Lidya Le
Clinical Operations
Lidya Le
Clinical Operations
Kevin Staffin
Quality Assurance
Kevin Staffin
Quality Assurance
Tuan Minh Nguyen, PhD
Biology
Tuan Minh Nguyen, PhD
Biology
Jessie Lin
Corporate Strategy &
Portfolio Management
Jessie Lin
Corporate Strategy &
Portfolio Management
Kristin Andrews, PhD
Computational Chemistry
Kristin Andrews, PhD
Kristin Andrews, PhD
Computational Chemistry
Gosia Riley
Clinical Operations
Gosia Riley
Clinical Operations
Alex Balcom
Chief Financial Officer
Alex Balcom
Alex Balcom
Chief Financial Officer
Darlene Noci, ALM
Chief Development Officer
Darlene Noci, ALM
Darlene Noci, ALM
Chief Development Officer
Jenn Fairbanks
Clinical Operations
Jenn Fairbanks
Clinical Operations
Christopher Cooper, PhD
Pharmaceutical Development
Christopher Cooper, PhD
Pharmaceutical Development
Shashank Kulkarni, PhD
Medicinal Chemistry
Shashank Kulkarni, PhD
Medicinal Chemistry
Benjamin Lane, PhD
Technical Operations
Benjamin Lane, PhD
Benjamin Lane, PhD
Technical Operations
Sibao Chen, PhD
Pharmaceutical
Development
Sibao Chen, PhD
Pharmaceutical
Development
Kari Andrews
Clinical Operations
Kari Andrews
Clinical Operations
Ray Kemper, PhD
Toxicology
Ray Kemper, PhD
Toxicology
Christopher Turner, MD
Chief Medical Officer
Christopher Turner, MD
Chief Medical Officer
Mikhaila Ruth
Human Resources
Mikhaila Ruth
Human Resources
Matthew Metivier
Human Resources
Matthew Metivier
Human Resources
Virginia Vetter
Regulatory Affairs
Virginia Vetter
Regulatory Affairs
James Porter, PhD
Chief Executive Officer
James Porter, PhD
James Porter, PhD
Chief Executive Officer
Sowjanya Mangipudi
Clinical Operations
Sowjanya Mangipudi
Clinical Operations
Greg Smith
Regulatory
Greg Smith
Regulatory

A Phase 1/2 study of NVL-520 in patients with advanced ROS1-positive NSCLC and other solid tumors.

A Phase 1/2 study of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors.

LEARN MORE ABOUT
OUR CLINICAL STUDIES